One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 17 January 2025, Novo Nordisk has since 6 February 2024 ...
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 11 unusual trades. Delving into the details, we found 72% ...
ST. PAUL (Valley News Live) - Attorney General Keith Ellison announced a settlement with Novo Nordisk that guarantees that all Minnesotans, with or without insurance, can buy Novo Nordisk’s ...
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback